Copyright
©The Author(s) 2024.
World J Gastroenterol. Aug 28, 2024; 30(32): 3766-3782
Published online Aug 28, 2024. doi: 10.3748/wjg.v30.i32.3766
Published online Aug 28, 2024. doi: 10.3748/wjg.v30.i32.3766
Figure 3 Forest plots.
A: Aspartate aminotransferase (AST); B: Mesenchymal stem cells source subgroups of AST levels; C: Animal model subgroup of AST levels; D: Mechanism subgroup of AST levels; E: Alanine aminotransferase (ALT); F: Mechanism subgroup of ALT levels; G and H: Hydroxyproline; I: Forest plot of type III collagen; J: Mechanism subgroup of transforming growth factor beta gene levels. MSCs: Mesenchymal stem cells; 95%CI: 95% confidence interval; BM-MSCs: Bone marrow mesenchymal stem cells; AT-MSCs: Adipose mesenchymal stem cells; PD-MSCs: Placental mesenchymal stem cells.
- Citation: Xu Y, Wang XS, Zhou XL, Lu WM, Tang XK, Jin Y, Ye JS. Mesenchymal stem cell therapy for liver fibrosis need “partner”: Results based on a meta-analysis of preclinical studies. World J Gastroenterol 2024; 30(32): 3766-3782
- URL: https://www.wjgnet.com/1007-9327/full/v30/i32/3766.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i32.3766